Stay updated with breaking news from Aat033. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data, which were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2022, includes results of 81 patients with gastrointestinal acute Graft-versus-Host Disease
MaaT Pharma received authorizations from French and German regulatory authorities to initiate its Phase 2b clinical trial evaluating MaaT033 in improving survival in patients receiving allogeneic
Data describe rapid, safe and robust microbiome engraftment1 of MaaT033 in the gut of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome undergoing intensive chemotherapy